Oncolytics Biotech Stock Price

0.11 (3.89%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncolytics Biotech Inc ONCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.11 3.89% 2.94 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.86 2.80 2.92 2.92 2.83
Bid Price Ask Price Spread News
2.71 2.94 0.23 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
957 257,135 $ 2.85 $ 733,176 509,868 1.52 - 4.83
Last Trade Time Type Quantity Stock Price Currency
19:49:21 2 $ 2.94 USD

Oncolytics Biotech Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 122.47M 41.66M 18.75M $ - $ - -0.78 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Oncolytics Biotech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.013.012.702.86349,983-0.07-2.33%
1 Month3.063.212.703.01444,219-0.12-3.92%
3 Months3.574.832.583.37892,105-0.63-17.65%
6 Months2.424.832.223.251,395,3100.5221.49%
1 Year1.884.831.522.961,077,1221.0656.38%
3 Years6.156.20280.3512.68678,762-3.21-52.2%
5 Years5.857.400.3512.70671,177-2.91-49.74%

Oncolytics Biotech Description

Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotype through innate and adaptive immune responses. Our clinical development plan is based on these two components of the mechanism of action, with a focus on obtaining regulatory approval as soon as possible.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.